As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsJohanna Mercier - Chief ...

The inaugural direct-to-consumer campaign for the injectable drug debuted earlier this year, centering around a TV ad featuring a remake of Ciara and Missy Elliott’s 2004 hit song “1, 2 Step”—now ...

Wall Street is mired in another panic over AI. And we contrarians are here for it. Our play? This closed end fund yielding ...

Poor shooting and untimely fouls ultimately doomed the Bowling Green Christian Academy’s varsity boys basketball team on ...

The VDH has not answered questions about how much money it erroneously overbilled a pharmaceutical manufacturer and may have to pay back, despite the issue triggering significant cuts to HIV services.

In March 2026, Meiji Seika Pharma Co., Ltd. reported that its selective PDE4 inhibitor morcamilast (development code ME3183; proposed international nonproprietary name) has received orphan medicinal ...

Merck's blockbuster immunotherapy Keytruda, which generates nearly half of its total revenue, is scheduled to lose U.S. patent protection in 2028, opening the door to lower-cost generic competition.

In this week's episode of the CNBC Changemakers and Power Players podcast, CNBC Senior Media and Tech Reporter Julia Boorstin spoke with Johanna Mercier, Chief Commercial & Corporate Affairs Officer ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.